Genetically altered fields as origin of locally recurrent head and neck cancer: A retrospective study

被引:131
作者
Tabor, MP
Brakenhoff, RH
Ruijter-Schippers, HJ
Kummer, JA
Leemans, CR
Braakhuis, BJM
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, Tumor Biol Sect, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands
关键词
D O I
10.1158/1078-0432.CCR-03-0632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Surgeons treating patients with head and neck squamous cell carcinoma (HNSCC) rely heavily on histology to decide whether the resection margins are tumor free and subsequent adjuvant treatments can be omitted. However, despite the presence of tumor-free margins, 10-30% of HNSCC patients still develop a locally recurrent tumor. Evidence is available that recurrent cancer develops from either (a) outgrowth of a relatively small number of tumor cells that have not been detected by the pathologist or (b) a precursor lesion in which additional genetic alterations have led again to invasive cancer. Experimental Design: In a retrospective study on 13 HNSCC cases, we analyzed the primary tumor, its surrounding histologically tumor-free resection margins, and local recurrences for loss of heterozygosity (22 microsatellite markers on 6 chromosomes) and TP53 mutations to determine the origin of the recurrent cancer. Results: A precursor lesion was absent in 5 of 13 (39%) cases, and the genetic similarity of the primary and recurrent cancer was high, providing evidence that residual cancer cells were the origin of recurrence. For the remaining eight cases (61%) a genetically related precursor lesion (field) was detected, and for five of these cases, evidence was found that both the primary and recurrent carcinoma originated from this field. The remaining three cases were less conclusive. Conclusions: This study explains the pathobiology of locally recurrent HNSCC in patients with histologically tumor-free resection margins and indicates that the development of novel therapies to decrease the local recurrence rates in HNSCC should not only be focused on eradicating residual cancer cells but also on the precursor lesions that are left behind.
引用
收藏
页码:3607 / 3613
页数:7
相关论文
共 30 条
[1]   Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions [J].
Braakhuis, BJM ;
Tabor, MP ;
Leemans, CR ;
van der Waal, I ;
Snow, GB ;
Brakenhoff, RH .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (02) :198-206
[2]  
Braakhuis BJM, 2003, CANCER RES, V63, P1727
[3]  
Califano J, 1999, CLIN CANCER RES, V5, P1862
[4]  
Califano J, 1996, CANCER RES, V56, P2488
[5]  
Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO
[6]  
2-H
[7]  
Hittelman WN, 2001, ANN NY ACAD SCI, V952, P1
[8]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[9]   PREVENTION OF 2ND PRIMARY TUMORS WITH ISOTRETINOIN IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
HONG, WK ;
LIPPMAN, SM ;
ITRI, LM ;
KARP, DD ;
LEE, JS ;
BYERS, RM ;
SCHANTZ, SP ;
KRAMER, AM ;
LOTAN, R ;
PETERS, LJ ;
DIMERY, IW ;
BROWN, BW ;
GOEPFERT, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (12) :795-801
[10]  
LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO